This tip sheet provides a list of actionable solutions to challenges immunization programs (IPs) and partners may face in increasing equitable access to birth dose immunizations (i.e., vaccine for hepatitis B and nirsevimab, the new monoclonal antibody to prevent Respiratory Syncytial Virus).
To identify barriers and success to 1) enrolling birthing institutions in the VFC Program and 2) implementing birth dose immunization products, AIM conducted roundtable discussions and key-informant interviews with immunization programs and partners. AIM hopes findings from these conversations will help partners work together to increase equitable access to existing and future birth dose immunization products for all infants.
